List view / Grid view
The global medical marijuana market will show impressive growth, a new report has said, but this could be hindered due to some doctors being reluctant to prescribe these products.
Dr Englund discusses his research into medical cannabis, highlighting a range of its potential uses. He also explores some of the challenges that can be faced in clinical trials when investigating cannabinoids.
Following guidance from the drugs advisory body NICE, two cannabis-based medications have been approved for treatment by the NHS in England.
Cannabinoids, their potential therapeutic uses and the research needed for medical cannabis were the topics of discussion at the ‘Medical cannabis: what UK doctors need to know’ event held last week.
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.
An event was held last week, exploring the manufacturing and potential of cannabinoids within the pharmaceutical industry.
The cannabidiol-based treatment EPIDYOLEX has been granted marketing authorisation from the European Commission.
An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this third piece, we discuss the future of the cannabinoid industry and how it will grow within the realm of pharmaceuticals.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.
This series investigates the growing interest from the pharmaceutical industry in cannabinoids. In this first piece, we hear from industry experts about the current situation of the ingredient on the pharmaceutical market.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
